Diagnostic delays in familial Mediterranean fever: a Juvenile Inflammatory Rheumatism (JIR) cohort study
- PMID: 39316109
- DOI: 10.1007/s00296-024-05706-1
Diagnostic delays in familial Mediterranean fever: a Juvenile Inflammatory Rheumatism (JIR) cohort study
Abstract
Several studies reported that Familial Mediterranean Fever (FMF) diagnosis may be missed or delayed even in countries with a high FMF prevalence. Our aim was to study on a large cohort of European FMF patients the frequency and associated factors of diagnosis delay. Clinical data were extracted from the Juvenile Inflammatory Rheumatism (JIR)-cohort. All FMF patients fulfilled Livneh Criteria and had been sequenced for MEFV exon 10. FMF-diagnostic delay (d-FMF) was defined as the duration between the onset of the symptoms and the diagnosis of more than 10 years. 960 FMF patients were enrolled: delayed diagnosis (d-FMF) was noted in 200 patients (20%). d-FMF patients were significantly older compared to non d-FMF with a median age of 46.4 years old vs. 15.5 (p < 0.0001). Women displayed more d-FMF compared to men (56 vs. 47%, p = 0.03). Clinical presentation during attacks was not statistically significant except for erysipelas-like erythema, which was higher among d-FMF patients (33 vs. 22%, p = 0.0003). The presence of one or two pathogenic MEFV mutation was not different between patients. Compared to other FMF, d-FMF patients displayed significantly more AA amyloidosis (10 vs. 2.6%, p < 0.0001) and received more biotherapy (18 vs. 3.8%, p < 0.0001). Twenty percent of FMF patients had a diagnostic delay >10 years, including more women. The differential diagnosis of abdominal attacks with menstrual pain may be an explanation, and erysipelas-like erythema may not be recognized as FMF by all practitioners.
Keywords: MEFV; Diagnostic delay; Familial Mediterranean Fever; Women.
© 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Conflict of interest statement
Declarations. Conflict of interest: The authors declare that they have no conflict of interest.
References
-
- Lancieri M, Bustaffa M, Palmeri S et al (2023) An update on Familial Mediterranean Fever. IJMS 24:9584. https://doi.org/10.3390/ijms24119584 - DOI - PubMed - PMC
-
- Ben-Chetrit E (2023) Old paradigms and new concepts in Familial Mediterranean fever (FMF): an update 2023. Rheumatology 63(2):309–318. https://doi.org/10.1093/rheumatology/kead439 - DOI
-
- Onen F (2006) Familial Mediterranean fever. Rheumatol Int 26:489–496. https://doi.org/10.1007/s00296-005-0074-3 - DOI - PubMed
-
- Savey L, Grateau G, Georgin-Lavialle S (2021) Fièvre méditerranéenne familiale en 2020. Nephrol Ther 17:S119–S125. https://doi.org/10.1016/j.nephro.2020.02.013 - DOI
-
- Livneh A, Langevitz P, Zemer D et al (1997) Criteria for the diagnosis of Familial Mediterranean Fever. Arthritis Rheum 40:1879–1885. https://doi.org/10.1002/art.1780401023 - DOI - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources